Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Summit Therapeutics PLC

www.summitplc.com

Latest From Summit Therapeutics PLC

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

Deal Watch: Pfizer Begins 2018 With Two Deals, Including ALS Tie-Up With Sangamo

In addition to its latest collaboration with Sangamo, Pfizer also teams with Arvinas on protein-degradation therapies. AstraZeneca sells off four mature products to ANI, while Summit enhances its antibiotic capabilities with Discuva buyout and out-licenses Latin American rights to ridinilazole.

Deals Business Strategies

Summit Completes 2017 With Discuva Buy

After good news on the funding front in the 2017 third quarter, UK biotech Summit Therapeutics has completed the year on a high, acquiring fellow UK biotech Discuva to add a novel antibiotic discovery platform to its expertise.

M & A Infectious Diseases

Tech Transfer Roundup: Arrakis Gets Penn IP Toward Small Molecule RNA Therapies

Canaan Partners-backed biotech will investigate the therapeutic potential of three-way junctions in folded RNA. UC Berkeley and Duke sign separate license agreements related to CRISPR gene-editing technology.

Deals Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • VASTox PLC
  • Summit PLC
  • Summit Corp. PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Summit Therapeutics PLC
  • Senior Management
  • Glyn Edwards, CEO
    Erik Ostrowski, CFO
    David Roblin, PhD, COO & CMO
  • Contact Info
  • Summit Therapeutics PLC
    Phone: (44) (0)1235 443 939
    136a Eastern Ave.
    Milton Park
    Abingdon, OX14 4SB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register